Kristin K. Brown

TL;DR: This work provides new insights into the mechanism of topoisomerase action and a platform for structure-based drug design of a new class of antibacterial agents against a clinically proven, but conformationally flexible, enzyme class.

TL;DR: The requirements for activation of NLRP1, an NLR protein associated with a number of human pathologies, are identified and the results describe key molecular pathways that regulateNLRP1 activity offer insight on how small sequence variations in NLR genes may influence human disease pathogenesis.

TL;DR: It is found that the mutant IDH1 is very efficient in this coupled reaction, with the ability to form αHG from isocitrate and NADP(+), and the wild type/wild type IDH2 is also able to catalyze this conversion, though it is much more sensitive to concentrations of isOCitrate.

TL;DR: The identification of GSK2194069, a potent and specific inhibitor of the β-ketoacyl reductase (KR) activity of hFAS is described; the characterization of its enzymatic and cellular mechanism of action; and its inhibition of human tumor cell growth are described.

TL;DR: The use of cell lysates expressing imine reductases operating at 1:1 stoichiometry for a variety of amines and carbonyls is reported.